Device Trial Radar · NCT03807531
A Study of the Temporary Spur Stent for the Treatment of Narrowing and Blockages in the Arteries Below the Knee
Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Jul 11, 2019
Primary completion
Apr 30, 2023
Study completion Jun 1, 2027
Sponsor
- Lead sponsor
- ReFlow Medical, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- ClinLogix. LLC
- First posted
- Jan 17, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the performance and safety of the Temporary Spur Stent System (TSS). The TSS is intended for use in conjunction with a commercially available drug coated balloon in the infrapopliteal arteries for the treatment of de novo or restenotic lesions. This study is a prospective, non-randomized, multicenter, single arm trial, with sites in New Zealand, Germany, and Switzerland. At least two and no more than 10 sites are expected to participate, with 100 subjects enrolled (no more than 40 at a single site). The study follow up will take place over a period of 365 days. A vessel recoil substudy will be included for a select group of subjects.
Conditions
- Peripheral Arterial Disease
Interventions
Temporary Spur Stent SystemDevice
Participating subjects that meet inclusion and exclusion criteria will undergo treatment of infrapopliteal occlusions and stenoses with the Temporary Spur Stent System according to protocol guidelines
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary patency of treated lesion sites by duplex ultrasound in subjects who are free from clinically driven TLR (target lesion revascularization)Time frame: 6 months
- Freedom from device and procedure-related death through 30 days post-procedureTime frame: 30 days
Locations
6 sites in 3 countries. Site status is shown where the registry gives one.
Klinikum Hochsauerland Klinik für Angiologie
Arnsberg, Germany
Universitats Herzzentrum Bad Krozingen
Bad Krozingen, Germany
Universitätsklinikum Leipzig
Leipzig, Germany
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.